Remiges Ventures

Remiges Ventures launched the RDiscovery Fund in April 2025 as a dedicated vehicle for incubating academic drug-discovery seeds. The fund operates through a Seattle office and a Tokyo office housed at the Global Life Science Hub, explicitly separating discovery-stage incubation from the firm's core venture capital activity. This bifurcated structure isolates early-stage scientific risk in a vehicle designed for nascent therapeutic programs.

Remiges Ventures concentrates on regenerative medicine, neurology, and biologic therapies, as evidenced by its 2025–2026 portfolio activity. Announced positions include Cyrano Therapeutics, a regenerative therapy for persistent smell loss, and Immunis, a secretome-based biologic developer targeting sarcopenia and Parkinson's disease dyskinesia. The firm's portfolio clustering suggests a thesis-driven focus on indications with neurodegeneration and tissue-repair mechanisms.

Remiges Ventures is structured as an asset manager and private equity firm, not a single-family office. It raises external capital through vehicles such as the RDiscovery Fund and maintains offices in Seattle, Cambridge, and Tokyo — an institutional infrastructure consistent with a fund manager. No principal names or family-wealth origins are publicly disclosed, confirming its third-party capital posture.

Remiges Ventures structures its activity primarily through direct venture creation and seed-stage investments, including its dedicated RDiscovery incubation vehicle. The firm's portfolio companies — such as Immunis and Cyrano Therapeutics — are direct positions rather than fund-of-funds allocations. No disclosures indicate an LP-in-funds program alongside its direct therapeutic company investments.

The RDiscovery Fund is a distinct incubation vehicle operating under the Remiges Ventures umbrella with its own Tokyo-based management and a separate Seattle office address. It was launched in April 2025 to incubate drug-discovery seeds sourced from academic institutions, while the core venture platform continues to make direct therapeutic company investments. This structural separation isolates discovery-stage program risk from later-stage portfolio holdings.